SPAC Mergers Take Biopharmas Public, But Valuations Often Sag Post-Closing
Deals Give Stock Market Access Without IPO
SPAC mergers can be lucrative but it can be difficult to maintain and increase valuations afterwards • Source: Alamy/Andrii Yalanskyi 
